Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hoth Therapeutics

0.8990
+0.04805.64%
Post-market: 0.8800-0.0190-2.11%19:57 EDT
Volume:121.11K
Turnover:105.01K
Market Cap:11.84M
PE:-0.70
High:0.9100
Open:0.8500
Low:0.8267
Close:0.8510
Loading ...

Hoth Therapeutics Advances Cancer Fighting Ht-Kit Program With New Patent Filing and Preclinical Study Initiation

THOMSON REUTERS
·
26 Mar

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

PR Newswire
·
26 Mar

Hoth Therapeutics to Revise Financial Statements Due to Auditing Errors

Dow Jones
·
26 Mar

Hoth Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
25 Mar

Hoth Therapeutics announces ‘positive’ results from study of HT-KIT

TipRanks
·
19 Mar

Hoth Therapeutics Announces Positive Preclinical Results for Ht-Kit in Aggressive Cancer Gastrointestinal Stromal Tumors (Gist). Ht-Kit Triggered Significant Tumor Cell Death as Early as 24 Hours Post-Treatment

THOMSON REUTERS
·
18 Mar

Hoth Therapeutics Inc: New Data Demonstrates Significant Reduction in Tumor Growth

THOMSON REUTERS
·
18 Mar

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

PR Newswire
·
18 Mar

BRIEF-Hoth Therapeutics Announces Plans To Submit Expanded Access Application For Ht-001 To Support Cancer Patients In Need

Reuters
·
10 Mar

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
10 Mar

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for Ht-001 to Support Cancer Patients in Need

THOMSON REUTERS
·
10 Mar

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

PR Newswire
·
10 Mar

Hoth Therapeutics Reports HT-001 Cream Efficacy in Case Study

MT Newswires Live
·
06 Mar

Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate

TIPRANKS
·
06 Mar

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

PR Newswire
·
06 Mar

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
05 Mar

BRIEF-Hoth Therapeutics Announces Positive Findings On GDNF's Potential As A Game-Changer In Obesity Treatment And Reduced Fatty Liver Disease

Reuters
·
04 Mar

Hoth Therapeutics Announces Positive Findings on Gdnf's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

THOMSON REUTERS
·
04 Mar

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

PR Newswire
·
04 Mar

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
11 Feb